75 mg, 100mg
Trade Name
Closa
Tablet
Request Type
Registration
Drug Type
Generic Drug
Approval Date
SFDA Approved Use
is a fixed-dose combination product.
is intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products:
• Unstable angina or non-ST elevation myocardial infarction in order to prevent early and long-term
atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischemia).
is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularization (surgical or PCI, with or without stent).
• ST-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. In this population, CLOGREX ASA has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.
is intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products:
• Unstable angina or non-ST elevation myocardial infarction in order to prevent early and long-term
atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischemia).
is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularization (surgical or PCI, with or without stent).
• ST-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. In this population, CLOGREX ASA has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.